Our goal was to examine whether bFGF treatment can contribute to the reversal of the detrimental impact of diabetes mellitus on ASCs and therefore, in the future, improve clinical outcome of therapies involving those cells. The gene discussed is FGF2; the disease is diabetes mellitus.